MorphoSys AG is trimming its pipeline and centralizing research and development activities at a hub in Germany in relation to its acquisition last year of Constellation Pharmaceuticals. The move means the company will close down US discovery biology and drug discovery as well as earlier-stage programs that were part of the Constellation pipeline, but it also enables the company to focus on later-stage programs that have made progress since the acquisition.
The German biotech company reported on 10 March a non-cash impairment charge of about €231m ($252.1m) after consolidation of research...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)